BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 15, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Australia builds national innovation database to chart course of new health tech

March 14, 2018
By Tamra Sami
PERTH, Australia – Australia is launching an online "innovation showcase" that aims to catalogue and track the progress of innovations in the pharmaceutical, medical technology and digital health space across Australia in real time on a public platform open to investors, health practitioners and the public.
Read More

J&J, Cook Medical expand Australia operations, cite top-notch science, high demand

March 8, 2018
By Tamra Sami

Australia builds national innovation database to chart course of new health tech

March 8, 2018
By Tamra Sami
PERTH, Australia – Australia is launching an online "innovation showcase" that aims to catalogue and track the progress of innovations in the pharmaceutical, medical technology and digital health space across Australia in real time on a public platform open to investors, health practitioners and the public.
Read More

Australia builds national database to chart the course of new health technology

March 6, 2018
By Tamra Sami

Mesoblast's stem cell therapy meets primary endpoint in phase III GVHD pediatric trial

Feb. 28, 2018
By Tamra Sami
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
Read More

Rhythm Biosciences' blood-based colon cancer test may offer alternative to fecal test

Feb. 26, 2018
By Tamra Sami

Mesoblast's stem cell therapy meets primary endpoint in phase III GVHD pediatric trial

Feb. 23, 2018
By Tamra Sami
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
Read More

Australia's NME approvals fall to five-year low in 2017

Feb. 16, 2018
By Tamra Sami
PERTH, Australia – In 2017, Australia's Therapeutic Goods Administration (TGA) approved the lowest number of new molecular entities since 2012 – just 34, compared to 42 in 2016 and 45 in 2015.
Read More

Admedus expands Cardiocel franchise in India as it builds on emerging markets strategy

Feb. 15, 2018
By Tamra Sami

Allergan pays $95M up front for Australian tissue repair firm Elastagen

Feb. 14, 2018
By Tamra Sami
PERTH, Australia – Allergan plc is acquiring Sydney-based Elastagen Pty Ltd., a private company with a tissue repair platform that complements Allergan's aesthetic and dermatology franchise.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing